Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

20.98USD
21 Apr 2017
Change (% chg)

$-0.34 (-1.59%)
Prev Close
$21.32
Open
$21.29
Day's High
$21.84
Day's Low
$20.94
Volume
3,887,873
Avg. Vol
4,761,061
52-wk High
$23.49
52-wk Low
$4.24

Select another date:

Wed, Mar 29 2017

BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan

* Exelixis further reduces indebtedness by repaying silicon valley bank term loan

BRIEF-Exelixis' cabozantinib granted orphan drug designation

* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma

BRIEF-Exelixis announces clinical trial collaboration with Roche

* Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors

BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab

* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors

BRIEF-Exelixis and Takeda enter into exclusive licensing agreement

* Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan

BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration

* Update on dispute between Exelixis and Genentech, a member of the Roche group

BRIEF-Exelixis announces Q3 and YTD 2016 financial results

* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update

Select another date:

More From Around the Web